Akums Drugs and Pharmaceuticals (NSE:AKUMS) Total Liabilities: ₹21,158 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
39 GF Score
Price ₹660.60
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals Total Liabilities?

Akums Drugs and Pharmaceuticals NSE:AKUMS -0.59% 39 Total Liabilities is ₹21,158 Mil as of Mar. 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review.

Akums Drugs and Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹21,158 Mil.

Akums Drugs and Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (₹19,908.64 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹21,158.44 Mil).

Akums Drugs and Pharmaceuticals's annual Total Liabilities declined from Mar. 2024 (₹27,958.79 Mil) to Mar. 2025 (₹10,498.31 Mil) but then increased from Mar. 2025 (₹10,498.31 Mil) to Mar. 2026 (₹21,158.44 Mil).

Akums Drugs and Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals Total Liabilities Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 24,438.77 25,431.53 27,958.79 10,498.31 21,158.44

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,498.31 0.00 19,908.64 0.00 21,158.44
NSE:AKUMS
39GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Akums Drugs and Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10947.57+(768.44+8956.36
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+486.07+0)
=21,158

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=54469.65-33311.21
=21,158

Akums Drugs and Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10947.57+(768.44+8956.36
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+486.07+0)
=21,158

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=54469.65-33311.21
=21,158

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹21,158 Mil mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Total Liabilities of ₹21,158 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Akums Drugs and Pharmaceuticals and its competitors.
Is Akums Drugs and Pharmaceuticals' Total Liabilities too high?
Akums Drugs and Pharmaceuticals' current Total Liabilities is ₹21,158 Mil. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Total Liabilities compare to ZTS?
Akums Drugs and Pharmaceuticals' Total Liabilities of ₹21,158 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current Total Liabilities is ₹21,158 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Total Liabilities of ₹21,158 Mil. The current Total Liabilities is ₹21,158 Mil. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Total Liabilities is ₹21,158 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score

Get the complete analysis for NSE:AKUMS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹660.60
Price